Dalpiciclib in advanced breast cancer

Hormone receptor-positive, HER2-negative advanced breast cancer is largely not curable. Anti-oestrogen agents improve the prognosis of patients with hormone receptor-positive, HER2-negative advanced breast cancer, but resistance eventually occurs. Targeting cyclin-dependent kinase 4 (CDK4) and CDK6 increases endocrine therapy efficacy, leading to the approval of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in the this treatment setting. 1 Spring LM Wander SA Andre F et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020; 395: 817-827 Summary Full Text Full Text PDF PubMed Scopus (180) Google Scholar Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialOur findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape. Full-Text PDF